Brenna G Hansen
Overview
Explore the profile of Brenna G Hansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
1439
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Brudno J, Maric I, Hartman S, Rose J, Wang M, Lam N, et al.
J Clin Oncol
. 2018 May;
36(22):2267-2280.
PMID: 29812997
Purpose Therapies with novel mechanisms of action are needed for multiple myeloma (MM). T cells can be genetically modified to express chimeric antigen receptors (CARs), which are artificial proteins that...
2.
Ali S, Shi V, Maric I, Wang M, Stroncek D, Rose J, et al.
Blood
. 2016 Jul;
128(13):1688-700.
PMID: 27412889
Therapies with novel mechanisms of action are needed for multiple myeloma (MM). B-cell maturation antigen (BCMA) is expressed in most cases of MM. We conducted the first-in-humans clinical trial of...
3.
Brudno J, Somerville R, Shi V, Rose J, Halverson D, Fowler D, et al.
J Clin Oncol
. 2016 Jan;
34(10):1112-21.
PMID: 26811520
Purpose: Progressive malignancy is the leading cause of death after allogeneic hematopoietic stem-cell transplantation (alloHSCT). After alloHSCT, B-cell malignancies often are treated with unmanipulated donor lymphocyte infusions (DLIs) from the...
4.
Kochenderfer J, Dudley M, Carpenter R, Kassim S, Rose J, Telford W, et al.
Blood
. 2013 Sep;
122(25):4129-39.
PMID: 24055823
New treatments are needed for B-cell malignancies persisting after allogeneic hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial of allogeneic T cells genetically modified to express a chimeric...